A method for determining a cancer treatment for a patient, comprising: determining a BH3 profile for the patient's cancer cell specimen, wherein the cancer is selected from acute myelogenous leukemia or multiple myeloma, and wherein determining the BH3 profile comprises permeabilizing the patient's cancer cells, determining a change in mitochondrial membrane potential upon contacting the permeabilized cells with one or more BH3 domain peptides; and correlating a loss of mitochondrial membrane potential with chemosensitivity of the cells to apoptosis-inducing chemotherapeutic agents; determining one or more clinical factors of the patient selected from the group consisting of age, cytogenetic status, performance, histological subclass, gender, and disease stage, and classifying the patient for likelihood of clinical response to one or more cancer treatments, wherein the likelihood of the clinical response is determined by assessing a percent priming, wherein the percent priming measures the response of the cancer cell specimen to said contacting with one or more BH3 domain peptides and the percent priming is defined by the following equation: % ⁢ Priming = 100 ∗ DMSO AUC − Peptide 1 AUC DMSO AUC − CCCP avg AUC Peptide 1 + 100 ∗ DMSO AUC − Peptide 2 AUC DMSO AUC − CCCP avg AUC Peptide 2 + ⋯ / n peptides wherein: AUC is either (i) the area under a curve of a homogenous time-resolved fluorescence (HTRF) measurement, or (ii) the mean signal intensity of a fluorescence activated cell sorting (FACS) measurement at a single time point that occurs between about 5 min and about 300 min after the start of said contacting, of said change in mitochondrial membrane potential; DMSO (dimethyl sulfoxide) is a baseline negative control; and CCCP (Carbonyl cyanide m -chlorophenyl hydrazone) is a chemical inhibitor of oxidative phosphorylation and comprises an effector of protein synthesis by serving as uncoupling agent of the proton gradient established during the normal activity of electron carriers in the electron transport chain in the mitochondria, and is a baseline positive control; Peptide is said one or more BH3 domain peptides; wherein the one or more clinical factors are selected to increase specificity and/or sensitivity of the BH3 profile for association with clinical response. determining a BH3 profile for the patient's cancer cell specimen, wherein the cancer is selected from acute myelogenous leukemia or multiple myeloma, and wherein determining the BH3 profile comprises permeabilizing the patient's cancer cells, determining a change in mitochondrial membrane potential upon contacting the permeabilized cells with one or more BH3 domain peptides; and correlating a loss of mitochondrial membrane potential with chemosensitivity of the cells to apoptosis-inducing chemotherapeutic agents; determining one or more clinical factors of the patient selected from the group consisting of age, cytogenetic status, performance, histological subclass, gender, and disease stage, and classifying the patient for likelihood of clinical response to one or more cancer treatments, wherein the likelihood of the clinical response is determined by assessing a percent priming, wherein the percent priming measures the response of the cancer cell specimen to said contacting with one or more BH3 domain peptides and the percent priming is defined by the following equation: % ⁢ Priming = 100 ∗ DMSO AUC − Peptide 1 AUC DMSO AUC − CCCP avg AUC Peptide 1 + 100 ∗ DMSO AUC − Peptide 2 AUC DMSO AUC − CCCP avg AUC Peptide 2 + ⋯ / n peptides wherein: AUC is either (i) the area under a curve of a homogenous time-resolved fluorescence (HTRF) measurement, or (ii) the mean signal intensity of a fluorescence activated cell sorting (FACS) measurement at a single time point that occurs between about 5 min and about 300 min after the start of said contacting, of said change in mitochondrial membrane potential; DMSO (dimethyl sulfoxide) is a baseline negative control; and CCCP (Carbonyl cyanide m -chlorophenyl hydrazone) is a chemical inhibitor of oxidative phosphorylation and comprises an effector of protein synthesis by serving as uncoupling agent of the proton gradient established during the normal activity of electron carriers in the electron transport chain in the mitochondria, and is a baseline positive control; Peptide is said one or more BH3 domain peptides; AUC is either (i) the area under a curve of a homogenous time-resolved fluorescence (HTRF) measurement, or (ii) the mean signal intensity of a fluorescence activated cell sorting (FACS) measurement at a single time point that occurs between about 5 min and about 300 min after the start of said contacting, of said change in mitochondrial membrane potential; (i) the area under a curve of a homogenous time-resolved fluorescence (HTRF) measurement, or (ii) the mean signal intensity of a fluorescence activated cell sorting (FACS) measurement at a single time point that occurs between about 5 min and about 300 min after the start of said contacting, DMSO (dimethyl sulfoxide) is a baseline negative control; and CCCP (Carbonyl cyanide m -chlorophenyl hydrazone) is a chemical inhibitor of oxidative phosphorylation and comprises an effector of protein synthesis by serving as uncoupling agent of the proton gradient established during the normal activity of electron carriers in the electron transport chain in the mitochondria, and is a baseline positive control; Peptide is said one or more BH3 domain peptides; wherein the one or more clinical factors are selected to increase specificity and/or sensitivity of the BH3 profile for association with clinical response.